What’s Telling Me to Buy GlaxoSmithKline Plc Today

Royston Wild considers the investment case for GlaxoSmithKline plc (LON: GSK).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today, I am looking at GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), and deciding whether the pharma stock offers the right prescription for glorious gains.

Pumping up the pipeline

GlaxoSmithKline reported last month that total sales rose just 2% on a constant currency basis in the second quarter, to £6.62bn. And operating profit fell 13% from the corresponding 2012 period to £1.44bn.

The company has suffered from major patent expirations across several key drugs in recent times, a phenomenon that drove earnings modestly lower last year. But GlaxoSmithKline has invested heavily in R&D to counter this problem and develop its product pipeline to facilitate future growth.

In the last quarter, the business received approval in the United States for its Breo Ellipta treatment for chronic obstructive pulmonary disease. It also got the go-ahead for its Tafinlar and Mekinist drugs for the treatment of metastatic melanoma. In total, GlaxoSmithKline is expecting Phase III data for 13 products this year.

Big trouble in not-so-little China

GlaxoSmithKline has been rocked in recent weeks by allegations of corruption against dozens of its employees, including senior executives, in China. The crisis has seen Herve Gisserot, the firm’s vice president for Europe, parachuted in to head up operations in the country amid allegations of rogue conduct.

The firm has been quick to distance itself from the scandal, commenting that it is ‘taking this matter very seriously and… co-operating fully with the Chinese authorities‘, and that it has ‘zero tolerance for any behaviour of this nature‘. Although it is early days in the investigation, and China represents a massive deal in terms of future earnings, GlaxoSmithKline is certainly making the right noises in terms of damage limitation.

Brace yourself for accelerating earnings

According to City forecasts, earnings are ready to resume their path higher from this year onwards following the difficulties of 2012. A 3% earnings per share advance is anticipated for 2013 before charging 10% higher next year.

The company currently changes hands on a P/E ratio of 14.7 for 2013, far in advance of major rivals such as AstraZeneca, which was recently dealing on a prospective readout of 7.9. However, the latter’s current rating well below the bargain benchmark of 10 is justified given its paltry pipeline and meagre near-term earnings prospects, particularly compared with those of its rival.

The right medication for meaty dividends

GlaxoSmithKline is liked among dividend seekers owing to its ability to lift the full-year dividend even in times of heavy earnings pressure in recent times. Indeed, the final shareholder payout last year was up almost 30% from that of 2008, and brokers expect dividends to keep moving higher over the medium term.

And the company currently offers a yield of 4.3% and 4.6% for this year and next, well above the prospective FTSE 100 average of 3.3%.

Whether or not you already hold shares in GlaxoSmithKline, you should check out this brand new and exclusive report which singles out even more FTSE 100 winners to really jump start your investment income.

Our “5 Dividend Winners To Retire On” wealth report highlights a selection of incredible stocks with an excellent record of providing juicy shareholder returns. Among our picks are top retail, pharmaceutical and utilities plays which we are convinced should continue to provide red-hot dividends. Click here to download the report — it’s 100% free and comes with no further obligation.

> Royston does not own shares in any of the companies mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Investing Articles

£10,000 invested in BAE Systems shares at the start of 2025 is now worth…

Harvey Jones's BAE System shares have smashed the market so far in 2025. Yet while this remains a core FTSE…

Read more »

A young black man makes the symbol of a peace sign with two fingers
Investing Articles

As UK shares plunge, dividend yields soar! These 2 income stocks look appealing

The stock market took a hit earlier this month, but it's not all doom and gloom. Mark Hartley uncovers two…

Read more »

Investing Articles

Here’s why I think investors should consider this FTSE 100 rival instead of Rolls-Royce shares

Rolls-Royce shares have had a great run, but I don't see much more gas in the tank. When thinking in…

Read more »

Dividend Shares

Here’s a 6-stock ISA portfolio that could make £1.55k in monthly passive income

Jon Smith outlines some of his favourite income stocks that could be used within an ISA to generate a 7%+…

Read more »

Investing Articles

Forecast: by April 2026, the Apple share price could turn £1,000 into…

The Apple share price is down almost 20% from the fallout of US tariffs, but has the market overreacted? Zaven…

Read more »

Investing Articles

Down 72%, can this former FTSE darling get its mojo back?

With luxury brands getting hit by weak consumer confidence and trade wars, Andrew Mackie examines the health of this FTSE…

Read more »

Investing Articles

Forecast: in just 12 months, the Sainsbury’s share price could turn £1,000 into…

J Sainsbury’s share price is tumbling as a rival retailer makes aggressive moves to recapture market share. But could this…

Read more »

Investing Articles

As stocks fall, is this a rare chance for investors to start earning a second income?

A sudden drawdown in the stock market can be great opportunity for investors looking for a second income. But some…

Read more »